Does Medica Cover Forteo? Coverage Rules, Costs, and What to Do If Denied

What Is Forteo and Why Is It So Tightly Managed?

Teriparatide (Forteo) is the synthetic N-terminal fragment of human parathyroid hormone. Rather than slowing bone breakdown the way bisphosphonates do, it directly stimulates new bone formation by activating osteoblasts. The FDA approved Forteo in November 2002 for postmenopausal women and men at high risk of fracture, and later extended the indication to glucocorticoid-induced osteoporosis [1].

The Clinical Evidence Driving Coverage Decisions

The key Fracture Prevention Trial (FPT) enrolled 1,637 postmenopausal women with prior vertebral fractures and showed that teriparatide 20 mcg/day reduced new vertebral fracture risk by 65% and nonvertebral fracture risk by 53% compared with placebo over a median 21 months [2]. Insurers and pharmacy benefit managers cite this trial when setting their high-risk patient criteria, because the absolute benefit is largest in patients who have already fractured.

Lumbar spine BMD increased by 9.7% and femoral neck BMD by 2.8% in the FPT teriparatide arm at 19 months [2]. Those numbers matter to Medica's medical directors, who use BMD improvement thresholds as surrogate endpoints when reviewing whether to continue prior authorization beyond year one.

Why Anabolic Agents Cost More to Insure

Bisphosphonates such as alendronate cost roughly $10 to $20 per month in generic form [3]. Forteo's 2024 wholesale acquisition cost sits near $3,500 per month, making it 150 to 300 times more expensive per patient-month. Specialty pharmacies and pharmacy benefit managers (PBMs) apply utilization management aggressively at that price point. Step therapy, prior authorization, and mandatory specialty pharmacy dispensing are all standard tools that reduce plan expenditure without denying access to patients who genuinely need the drug [4].

Medica's Formulary Structure and Where Forteo Lives

Medica Health Plans operates across Minnesota, Iowa, Kansas, Missouri, Nebraska, North Dakota, South Dakota, and Wisconsin. The company administers both commercial group plans and Medicare Advantage (MA) plans, and formulary placement can differ substantially between those lines of business.

Commercial Plan Formulary Tier

On most Medica commercial formularies, Forteo is placed at the specialty tier (Tier 4 or Tier 5). Member cost sharing at the specialty tier is typically a percentage coinsurance (20%, 35%) rather than a flat copay, with a per-fill out-of-pocket exposure that can reach $700, $1,200 after deductible in high-deductible plans. The specific tier assignment changes with each plan year, so always verify the current Summary of Benefits and Coverage (SBC) or call Medica member services at the number on the back of your insurance card.

Medicare Advantage Formulary Tier

Under Medicare Part D rules incorporated into Medica's MA-PD plans, specialty drugs are governed by the CMS formulary guidelines and the Low Income Subsidy (LIS) structure [5]. Forteo typically lands in Tier 5 (specialty) of Medica's MA-PD plans. The standard cost-sharing for non-LIS enrollees in the catastrophic phase drops to 5% after the out-of-pocket threshold is met, which for 2025 is $2,000 under the Inflation Reduction Act cap [6].

Step Therapy Requirements

Medica, like most large commercial carriers, requires step therapy before approving Forteo. The standard step is 6 consecutive months of an oral bisphosphonate, most commonly alendronate 70 mg once weekly. Risedronate 35 mg weekly or ibandronate 150 mg monthly are acceptable alternatives if alendronate is contraindicated. Documented intolerance (esophageal stricture, severe GERD, renal insufficiency with eGFR <35 mL/min) or documented clinical failure (new fracture on therapy, continued BMD decline of more than 3% at the spine or hip) can bypass step therapy [7].

Prior Authorization Criteria: What the Medical Record Must Show

Getting prior authorization (PA) approved on the first submission requires that your clinician's documentation matches Medica's specific criteria. Missing even one element can trigger an automatic denial that takes weeks to appeal.

Core Clinical Criteria

Medica's PA criteria for Forteo on commercial plans typically require ALL of the following [8]:

• Diagnosis of osteoporosis confirmed by DXA scan with T-score <-2.5 at the lumbar spine, total hip, or femoral neck, OR a fragility fracture within the past 24 months
• Prescriber is an endocrinologist, rheumatologist, or primary care physician with documented osteoporosis management experience
• Documentation of bisphosphonate trial of at least 6 months (or documented contraindication or intolerance)
• Patient age 18 or older
• Not currently pregnant

For glucocorticoid-induced osteoporosis (GIOP), Medica generally requires documentation of prednisone 5 mg/day (or equivalent) for 3 or more consecutive months plus a T-score <-2.5 or fragility fracture, consistent with the American College of Rheumatology 2022 GIOP guidelines [9].

High-Risk Fast-Track Criteria

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) defines "imminent fracture risk" as patients who have sustained a fracture within the past 12 months [10]. Many Medica plans have adopted this language to allow PA approval without step therapy for patients who have already fractured on bisphosphonate therapy or who present with two or more vertebral fractures at diagnosis. Submitting the radiology report and DXA alongside the PA request, rather than waiting for Medica to request them, shortens the review cycle by 3 to 5 business days on average.

How Long PA Approval Lasts

Initial approvals are typically valid for 6 months. Renewal PA (sometimes called continuation authorization) requires documentation of treatment response: a follow-up DXA showing stable or improved BMD, or a clinical note confirming no new fractures and ongoing treatment adherence. The FDA label caps lifetime Forteo use at 24 months total [1], so most plans will not approve a third year under any circumstance.

What Medica Will Pay and What You Will Owe

Calculating Your Real Out-of-Pocket Cost

Assume a Medica commercial plan with a $1,500 individual deductible and 25% specialty coinsurance after deductible, and an out-of-pocket maximum of $7,500. Forteo's WAC near $3,500/month means:

• Months 1: You pay the full $1,500 deductible, then 25% of approximately $2,000 remaining = $500. Total month 1: $2,000.
• Months 2 to 3: You pay 25% of $3,500 = $875/month. Total months 2 to 3: $1,750.
• Month 4 onward: You have likely reached or approached the $7,500 OOP max, so cost sharing drops to $0 for the rest of the plan year.

These figures reset on January 1 each year. Patients who start Forteo in October face three expensive months before a reset. Starting in January allows full OOP max protection through December.

Medicare Advantage Patients in 2025

The Inflation Reduction Act's $2,000 Part D OOP cap took effect January 1, 2025 [6]. For Medica MA-PD enrollees, that means Forteo costs cannot exceed $2,000 annually regardless of list price once you are past the coverage gap. The Medicare Extra Help (LIS) program reduces this further for qualifying low-income beneficiaries.

Copay Assistance and Patient Support Programs

Eli Lilly's Forteo Savings Card

Eli Lilly offers a savings card for commercially insured patients that can reduce monthly out-of-pocket costs to as low as $25 per fill for eligible patients [11]. The card is not valid for Medicare, Medicaid, TRICARE, or any government-funded insurance. Eligibility and maximum annual savings limits change annually, so verify current terms at Lilly's official program page or by calling 1-800-545-5979.

Patient Assistance Program (PAP)

Uninsured or underinsured patients with household income at or below 400% of the federal poverty level may qualify for Lilly Cares, which provides Forteo at no cost [11]. Medica patients who are denied coverage and exhaust appeals may use this program during the gap period.

NeedyMeds and RxAssist Databases

Independent nonprofit databases at NeedyMeds.org and RxAssist.org catalog additional state pharmaceutical assistance programs (SPAPs) that may stack with Medica coverage. Several states in Medica's operating territory (Minnesota, Wisconsin) have SPAPs that cover specialty drug cost sharing for qualifying older adults [12].

What to Do If Medica Denies Forteo

Denials fall into three categories: formulary exclusion, PA denial, or step therapy denial. Each has a distinct appeal pathway.

Step 1: Request the Denial Rationale in Writing

Within 3 business days of a denial, Medica must provide a written Explanation of Benefits (EOB) or denial letter stating the specific reason and the applicable plan criteria. Federal law under ERISA (for employer-sponsored plans) and the ACA requires this [13]. The denial letter will cite the specific formulary rule or clinical criterion not met.

Step 2: File a Coverage Determination or Level 1 Appeal

For commercial plans, submit a Level 1 internal appeal within 180 days of the denial. Include:

• A letter of medical necessity from the prescriber citing the FPT trial data [2] and the BHOF clinical practice guidelines [10]
• DXA scan report showing T-score and any interval change
• Documentation of bisphosphonate trial or contraindication
• Any fracture radiology reports

For Medicare Advantage plans, the appeal process is a Coverage Determination, then a Redetermination, then an Independent Review Entity (IRE) review through Maximus Federal Services [5]. Time limits are strict: standard redetermination takes 60 days; expedited (for urgent need) takes 72 hours.

Step 3: External Review

If the Level 1 or Level 2 internal appeal fails, commercially insured patients in most states have the right to an independent external review through the state insurance commissioner [13]. Minnesota, where Medica is headquartered, has a strong external review process administered by the Minnesota Department of Commerce. External review overturn rates for specialty drugs in osteoporosis average approximately 30%, 40% based on published state data.

Step 4: Peer-to-Peer Review

Ask the prescribing physician to request a peer-to-peer (P2P) call with Medica's medical director before or during the appeal. P2P calls are particularly effective when the prescriber can cite specific trial data. The BHOF states in its 2022 clinical practice guidelines: "Anabolic therapy should be considered first-line in patients at very high fracture risk, defined as recent fracture, very low BMD (T-score <-3.0), or multiple fractures" [10]. Quoting this language directly in a P2P call frequently resolves PA denials that a written appeal alone would not.

The HealthRX clinical team developed the following four-step decision framework for prescribers submitting Forteo PA requests to Medica. Assembling all four elements before initial submission reduces denial rates compared to submitting the PA without supporting documentation.

HealthRX Forteo PA Submission Checklist (Medica-Specific):

1. DXA report (within 24 months) showing T-score at the lumbar spine and total hip, with the radiologist's interpretation letter
2. Fracture history documentation: radiology reports or hospital discharge summaries for any fragility fracture within the past 24 months
3. Bisphosphonate trial documentation: pharmacy fill records or prescriber notes showing at least 6 months of use (or a signed statement of contraindication citing the specific clinical reason)
4. Prescriber attestation letter citing BHOF 2022 guidelines [10] and the FPT fracture reduction data (65% reduction in vertebral fractures, 53% in nonvertebral fractures) [2]

Alternatives to Forteo That Medica May Prefer

If Forteo is denied and appeals fail, these alternatives are worth discussing with your clinician.

Tymlos (Abaloparatide)

Abaloparatide (Tymlos, Radius Health) is a related anabolic PTH receptor agonist approved by the FDA in April 2017 [14]. The ACTIVE trial (N=2,463) showed a 43% reduction in new vertebral fractures versus placebo at 18 months [14]. Medica's formulary may place Tymlos at a lower specialty tier than Forteo in some plan years, making it a cost-effective alternative that still provides anabolic bone-building activity. Both drugs share the 2-year lifetime cap.

Prolia (Denosumab)

Denosumab 60 mg subcutaneous injection every 6 months (Prolia, Amgen) is an antiresorptive RANK-L inhibitor. The FREEDOM trial (N=7,808) showed a 68% reduction in vertebral fracture risk at 3 years [15]. Prolia typically sits at a lower specialty tier than Forteo on Medica formularies and has a more permissive PA pathway. It is not an anabolic agent, so it does not build new bone the way teriparatide does, but for patients whose primary goal is fracture prevention rather than BMD recovery, Prolia is a strong option.

Reclast (Zoledronic Acid)

Zoledronic acid 5 mg IV once yearly (Reclast) is a bisphosphonate administered in an outpatient infusion setting. The HORIZON-PFT trial (N=7,736) showed a 70% relative risk reduction in morphometric vertebral fractures at 3 years [16]. It bypasses adherence issues and avoids upper GI side effects. Medica typically covers it at a non-specialty medical benefit tier (billed under the medical benefit, not the pharmacy benefit), which often means lower cost sharing.

Switching Therapy: Sequential Treatment After Forteo

The 2023 AACE/ACE Clinical Practice Guidelines for postmenopausal osteoporosis state that anabolic therapy should be followed by antiresorptive treatment to prevent the rapid bone loss that occurs after teriparatide is discontinued [17]. Typically, zoledronic acid 5 mg IV or denosumab 60 mg subcutaneous is started within 12 months of stopping Forteo. Medica's PA criteria for the sequential antiresorptive are generally straightforward once the prescriber documents prior Forteo use and treatment duration.

BMD gains achieved during teriparatide can be largely preserved with subsequent bisphosphonate therapy. A 2020 meta-analysis of 12 randomized controlled trials (N=3,418 combined) found that switching to zoledronic acid after teriparatide maintained lumbar spine BMD gains within 1.2% over 24 months of follow-up [18].

Biosimilars and the Future of Teriparatide Coverage

No FDA-approved AB-rated generic or interchangeable biosimilar of teriparatide was available under the Forteo brand as of early 2025. However, Alvogen and Sun Pharma have pursued teriparatide biosimilar pathways under the 505(b)(2) route [19]. If a biosimilar reaches market and receives therapeutic equivalence designation, Medica is likely to require substitution at the pharmacy, similar to the pattern seen with insulin biosimilars in 2022 to 2024. Prescribers who believe brand Forteo is medically necessary over a biosimilar will need to submit a separate dispensing-as-written (DAW) exception.

Verifying Your Specific Medica Plan Coverage Today

Medica updates its formularies on January 1 of each plan year and may make mid-year updates for newly approved drugs or significant pricing changes. Three steps to confirm current Forteo coverage before your prescription is sent:

1. Log into your Medica member portal at medica.com and use the drug cost estimator with the exact GPI code for teriparatide (teriparatide 20 mcg/80 mcg/mL subcutaneous solution, NDC 00002-8468-01 for the Forteo 2.4 mL prefilled pen).
2. Call Medica pharmacy services at the number on your insurance card and ask for the specific PA criteria sheet for teriparatide. Request a fax copy for your prescriber.
3. Have your prescriber's office contact the specialty pharmacy (typically Walgreens Specialty, CVS Specialty, or Accredo, depending on your plan's designated specialty network) to initiate a benefits investigation (BI) before the PA is submitted. A BI takes 24 to 72 hours and confirms real-time coverage, tier placement, and expected cost sharing.

A BHOF position statement notes that "treatment with approved pharmacologic agents reduces vertebral fractures by 40%, 70% and hip fractures by 20%, 50% in high-risk populations" [10]. For patients who qualify, gaining access to Forteo through a successful PA and appeal process is clinically meaningful, not administrative paperwork. DXA scans every 1 to 2 years during Forteo therapy, per the 2019 ISCD Official Positions, allow both the prescriber and Medica to confirm therapeutic response and support continued authorization [20].